A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
Penfluridol, a diphenylbutylpiperidene derivative, is a new long acting neuroleptic, administered orally, once weekly. It is marketed in several European countries and has been used successfully in the treatment of various acute psychoses, for severely ill chronic schizophrenic patients, and as maintenance therapy for chronic schizophrenic patients. The present study was designed to compare, in a double-blind fashion, the efficacy of penfluridol and fluphenazine decanoate in the maintenance therapy of schizophrenic outpatients.
D000328:Adult; D000553:Ambulatory Care; D002908:Chronic Disease; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005476:Fluphenazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010395:Penfluridol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*
D010880:Piperidines; D010395:Penfluridol; D005476:Fluphenazine